CytoDyn Inc. (CYDY) Set to Host Conference Call on
Post# of 154759
(Total Views: 4247)
Posted On: 01/04/2017 5:14:23 PM
CytoDyn Inc. (CYDY) Set to Host Conference Call on January 5, 2017
In a news release issued late Tuesday, CytoDyn Inc. (OTCQB: CYDY), a biotechnology company focused on the development of new antibody therapies for combatting human immunodeficiency virus (HIV) infection, announced that its management team will be hosting an investment community conference call on Thursday, January 5, 2017, at 4:00 pm EST.
The call is expected to feature an update on developments related to CytoDyn’s clinical and regulatory programs. The company will also be posting to its website (www.CytoDyn.com) a “Letter to Shareholders and Friends” from Nader Pourhassan Ph.D., president and CEO of CytoDyn. This letter, which will also be made available tomorrow, is expected to include a review of the company’s recent progress as well as insight into CytoDyn’s goals and milestones for the coming year.
To participate in tomorrow’s conference call, investors should dial 877-407-2986 (U.S./Canada) or 201-378-4916 (international). Alternatively, a live audio webcast may also be accessed under the Investors section/IR Calendar of CytoDyn’s corporate website. The company encourages web participants to visit its website at least 15 minutes prior to the start of the call in order to register and install any necessary software.
For those unable to attend the live call, the audio webcast will be archived for 60 days on CytoDyn’s corporate website. A replay of the conference call will also be made available until March 5, 2017. To access this replay, interested parties may dial 877-660-6853 (U.S./Canada) or 201-612-7415 (international); Conference ID: 13652328.
Tomorrow’s conference call comes less than a month after CytoDyn announced the treatment of the first several patients in its ongoing Phase 3 clinical trial of PRO 140 as a single-agent maintenance therapy in virally suppressed subjects with HIV. The new trial, which Pourhassan called “nearly a duplicate of [CytoDyn’s] Phase 2b monotherapy trial with an additional objective of investigating why some R5 patients did not respond to this therapy as well as others,” is likely to “provide essential data to support the continued clinical and regulatory advancement of PRO 140.”
Notably, data from this Phase 3 trial is expected to be submitted as part of CytoDyn’s upcoming Biologics License Application (BLA) for PRO 140 as a combination therapy with the current standard-of-care, highly active antiretroviral therapy (HAART). In addition to providing potential cost savings, this dual use of clinical data will facilitate “the fastest path to regulatory approval which is an expected submission of the rolling BLA in 2017,” according to Pourhassan.
For more information, visit www.CytoDyn.com
Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer
In a news release issued late Tuesday, CytoDyn Inc. (OTCQB: CYDY), a biotechnology company focused on the development of new antibody therapies for combatting human immunodeficiency virus (HIV) infection, announced that its management team will be hosting an investment community conference call on Thursday, January 5, 2017, at 4:00 pm EST.
The call is expected to feature an update on developments related to CytoDyn’s clinical and regulatory programs. The company will also be posting to its website (www.CytoDyn.com) a “Letter to Shareholders and Friends” from Nader Pourhassan Ph.D., president and CEO of CytoDyn. This letter, which will also be made available tomorrow, is expected to include a review of the company’s recent progress as well as insight into CytoDyn’s goals and milestones for the coming year.
To participate in tomorrow’s conference call, investors should dial 877-407-2986 (U.S./Canada) or 201-378-4916 (international). Alternatively, a live audio webcast may also be accessed under the Investors section/IR Calendar of CytoDyn’s corporate website. The company encourages web participants to visit its website at least 15 minutes prior to the start of the call in order to register and install any necessary software.
For those unable to attend the live call, the audio webcast will be archived for 60 days on CytoDyn’s corporate website. A replay of the conference call will also be made available until March 5, 2017. To access this replay, interested parties may dial 877-660-6853 (U.S./Canada) or 201-612-7415 (international); Conference ID: 13652328.
Tomorrow’s conference call comes less than a month after CytoDyn announced the treatment of the first several patients in its ongoing Phase 3 clinical trial of PRO 140 as a single-agent maintenance therapy in virally suppressed subjects with HIV. The new trial, which Pourhassan called “nearly a duplicate of [CytoDyn’s] Phase 2b monotherapy trial with an additional objective of investigating why some R5 patients did not respond to this therapy as well as others,” is likely to “provide essential data to support the continued clinical and regulatory advancement of PRO 140.”
Notably, data from this Phase 3 trial is expected to be submitted as part of CytoDyn’s upcoming Biologics License Application (BLA) for PRO 140 as a combination therapy with the current standard-of-care, highly active antiretroviral therapy (HAART). In addition to providing potential cost savings, this dual use of clinical data will facilitate “the fastest path to regulatory approval which is an expected submission of the rolling BLA in 2017,” according to Pourhassan.
For more information, visit www.CytoDyn.com
Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer
(0)
(0)